Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 161Neoplasm Metastasis 22Neoplasms 20Advanced Breast Cancer 13Ovarian Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Hereditary Sensory and Autonomic Neuropathies 9Endometrial Neoplasms 8Triple Negative Breast Neoplasms 7Colorectal Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Recurrence 4Neoplasms by Site 4Multiple Endocrine Neoplasia Type 1 4Breast Diseases 4Small Cell Lung Carcinoma 3Head and Neck Neoplasms 3Carcinoma, Ovarian Epithelial 3Uterine Neoplasms 2Stomach Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Liposarcoma 2HER2-positive Metastatic Breast Cancer 2Advanced Solid Tumors 2Advanced Solid Tumor 2Urologic Neoplasms 1

Interventions

zenocutuzumab 2seribantumab 2pembrolizumab 1patritumab 1osimertinib 1exemestane 1cemiplimab 1Vinorelbine 1Vascular Endothelial Growth Factor A 1Trastuzumab 1Paroxetine 1Paclitaxel 1Letrozole 1Itraconazole 1Fulvestrant 1Erlotinib Hydrochloride 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lethal Congenital Contracture Syndrome 2 × Fulvestrant × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡